Role of Obesity in Barrett's Esophagus and Cancer

Surgical Oncology Clinics of North America

Volumn 18, Issue 3, 2009, Pages 439-452

  Murray, Liam ^a   Romero, Yvonne ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

Adiposity; Barrett's esophagus; Esophageal adenocarcinoma; Obesity; Reflux esophagitis

Indexed keywords

ABDOMINAL OBESITY; BARRETT ESOPHAGUS; BODY FAT DISTRIBUTION; BODY MASS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; FOOD REGURGITATION; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INTESTINE METAPLASIA; OBESITY; REVIEW; ROUX Y ANASTOMOSIS; WEIGHT CONTROL; WEIGHT REDUCTION;

ADENOCARCINOMA; ADIPOKINES; BARRETT ESOPHAGUS; BODY FAT DISTRIBUTION; COCARCINOGENESIS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; EVIDENCE-BASED PRACTICE; GASTROESOPHAGEAL REFLUX; GHRELIN; HUMANS; INCIDENCE; OBESITY; PRECANCEROUS CONDITIONS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 66149117014     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.03.010     Document Type: Review

References (80)

1. Blot W.J., and McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin Orthod 26 5 Suppl 15 (1999) 2-8
2. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48 3 (2001) 304-309
3. van Soest E.M., Dieleman J.P., Siersema P.D., et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 54 8 (2005) 1062-1066
4. Hampel H., Abraham N.S., and El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143 3 (2005) 199-211
5. Jacobson B.C., Somers S.C., Fuchs C.S., et al. Body mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 354 22 (2006) 2340-2348
6. Jung H.K., Halder S., McNally M., et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 26 3 (2007) 453-461
7. Cremonini F., Locke III G.R., Schleck C.D., et al. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. Neurogastroenterol Motil 18 11 (2006) 987-994
8. Corley D.A., Kubo A., and Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 56 6 (2007) 756-762
9. Kang M.S., Park D.I., Oh S.Y., et al. Abdominal obesity is an independent risk factor for erosive esophagitis in a Korean population. J Gard Hist 22 10 (2007) 1656-1661
10. Lee H.L., Eun C.S., Lee O.Y., et al. Association between GERD-related erosive esophagitis and obesity. J Clin Gastroenterol 42 6 (2008) 672-675
11. Kjellin A., Ramel S., Rossner S., et al. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol 31 11 (1996) 1047-1051
12. Fraser-Moodie C.A., Norton B., Gornall C., et al. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 34 4 (1999) 337-340
13. Murray F.E., Ennis J., Lennon J.R., et al. Management of reflux oesophagitis: role of weight loss and cimetidine. Ir J Med Sci 160 1 (1991) 2-4
14. Mathus-Vliegen E.M., and Tygat G.N. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol 37 11 (2002) 1246-1252
15. Reis G.M., Savassi-Rocha P.R., Nogueira A.M., et al. Histological esophagitis before and after surgical treatment of morbid obesity (capella technique): a prospective study. Obes Surg 18 4 (2008) 367-370
16. Stein D.J., El-Serag H.B., Kuczynski J., et al. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther 22 10 (2005) 1005-1010
17. Bu X., Ma Y., Der R., et al. Body mass index is associated with Barrett esophagus and cardiac mucosal metaplasia. Dig Dis Sci 51 9 (2006) 1589-1594
18. Cook M.B., Greenwood D.C., Hardie L.J., et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 103 2 (2008) 292-300
19. Anderson L.A., Watson R.G., Murphy S.J., et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 13 10 (2007) 1585-1594
20. Smith K.J., O'Brien S.M., Smithers B.M., et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 14 11 Pt 1 (2005) 2481-2486
21. Solaymani-Dodaran M., Logan R.F., West J., et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53 8 (2004) 1070-1074
22. Edelstein Z.R., Farrow D.C., Bronner M.P., et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 133 2 (2007) 403-411
23. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 133 1 (2007) 34-41 [quiz 311]
24. Gerson L.B., Ullah N., Fass R., et al. Does body mass index differ between patients with Barrett's oesophagus and patients with chronic gastro-oesophageal reflux disease?. Aliment Pharmacol Ther 25 9 (2007) 1079-1086
25. Lagergren J., Bergstrom R., and Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130 11 (1999) 883-890
26. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90 2 (1998) 150-155
27. Corley D.A., Kubo A., and Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 17 2 (2008) 352-358
28. Kubo A., and Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15 5 (2006) 872-878
29. Abnet C.C., Freedman N.D., Hollenbeck A.R., et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 44 3 (2008) 465-471
30. Renehan A.G., Tyson M., Egger M., et al. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 9612 (2008) 569-578
31. MacInnis R.J., English D.R., Hopper J.L., et al. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Control 118 10 (2006) 2628-2631
32. Crane S.J., Locke III G.R., Harmsen W.S., et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol 102 8 (2007) 1596-1602
33. Chak A., Lee T., Kinnard M.F., et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 51 3 (2002) 323-328
34. Romero Y., Cameron A.J., Locke III G.R., et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 113 5 (1997) 1449-1456
35. de Jonge P.J., Steyerberg E.W., Kuipers E.J., et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 101 7 (2006) 1421-1429
36. Oberg S., Wenner J., Johansson J., et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Sci 242 1 (2005) 49-54
37. Vaughan T.L., Kristal A.R., Blount P.L., et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 11 8 (2002) 745-752
38. Risques R.A., Vaughan T.L., Li X., et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 12 (2007) 2649-2655
39. Olliver J.R., Hardie L.J., Gong Y., et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 14 3 (2005) 620-625
40. Jin Z., Hamilton J.P., Yang J., et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev 17 1 (2008) 111-117
41. Jin Z., Olaru A., Yang J., et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 13 21 (2007) 6293-6300
42. Kristal A.R., Blount P.L., Schenk J.M., et al. Low fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev 14 10 (2005) 2377-2383
43. Houghton S.G., Romero Y., and Sarr M.G. Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis 4 1 (2008) 1-4 [discussion: 4-5]
44. Stene-Larsen G., Weberg R., Froyshov Larsen I., et al. Relationship of overweight to hiatus hernia and reflux oesophagitis. Scand J Gastroenterol 23 4 (1988) 427-432
45. Mercer C.D., Wren S.F., DaCosta L.R., et al. Lower esophageal sphincter pressure and gastroesophageal pressure gradients in excessively obese patients. J Microencapsul 18 3-4 (1987) 135-146
46. Mercer C.D., Rue C., Hanelin L., et al. Effect of obesity on esophageal transit. Am J Sci 149 1 (1985) 177-181
47. Wu J.C., Mui L.M., Cheung C.M., et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 132 3 (2007) 883-889
48. El-Serag H.B., Tran T., Richardson P., et al. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 41 8 (2006) 887-891
49. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 6 (2004) 2548-2556
50. Vega G.L., Adams-Huet B., Peshock R., et al. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 91 11 (2006) 4459-4466
51. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 9418 (2004) 1346-1353
52. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 9113 (1998) 1393-1396
53. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 5350 (1998) 563-566
54. Kaaks R., Toniolo P., Akhmedkhanov A., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92 19 (2000) 1592-1600
55. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91 7 (1999) 620-625
56. Cheng P., Gong J., Wang T., et al. Gene expression in rats with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal reflux. World J Gastroenterol 11 33 (2005) 5117-5122
57. Iravani S., Zhang H.Q., Yuan Z.Q., et al. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol 34 10 (2003) 975-982
58. Di Martino E., Wild C.P., Rotimi O., et al. IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers 11 6 (2006) 547-561
59. Siahpush S.H., Vaughan T.L., Lampe J.N., et al. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 11 (2007) 2387-2395
60. Barb D., Williams C.J., Neuwirth A.K., et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 86 3 (2007) s858-s866
61. Tworoger S.S., Eliassen A.H., Kelesidis T., et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 92 4 (2007) 1510-1516
62. Dal Maso L., Augustin L.S., Karalis A., et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89 3 (2004) 1160-1163
63. Cust A.E., Kaaks R., Friedenreich C., et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 92 1 (2007) 255-263
64. Wei E.K., Giovannucci E., Fuchs C.S., et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97 22 (2005) 1688-1694
65. Wolf A.M., Wolf D., Rumpold H., et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323 2 (2004) 630-635
66. Konturek P.C., Burnat G., Rau T., et al. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 53 3 (2008) 597-605
67. Kendall B.J., Macdonald G.A., Hayward N.K., et al. Leptin and the risk of Barrett's oesophagus. Gut 57 4 (2008) 448-454
68. Thomas T., Burguera B., Melton III L.J., et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 49 10 (2000) 1278-1284
69. Ogunwobi O., Mutungi G., and Beales I.L. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147 9 (2006) 4505-4516
70. Beales I.L., and Ogunwobi O.O. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 274 1-2 (2007) 60-68
71. Francois F., Roper J., Goodman A.J., et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 57 1 (2008) 16-24
72. Garofalo C., and Surmacz E. Leptin and cancer. J Comp Psychol 207 1 (2006) 12-22
73. Stattin P., Palmqvist R., Soderberg S., et al. Plasma leptin and colorectal cancer risk: a prospective study in northern Sweden. Oncol Rep 10 6 (2003) 2015-2021
74. Stattin P., Soderberg S., Biessy C., et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat 86 3 (2004) 191-196
75. Wren A.M., Seal L.J., Cohen M.A., et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 12 (2001) 5992-5995
76. Isomoto H., Ueno H., Saenko V.A., et al. Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. Am J Gastroenterol 100 8 (2005) 1711-1720
77. Nwokolo C.U., Freshwater D.A., O'Hare P., et al. Plasma ghrelin following cure of Helicobacter pylori. Gut 52 5 (2003) 637-640
78. Tschop M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 4 (2001) 707-709
79. Dornonville de la Cour C., Lindstrom E., Norlen P., et al. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 120 1-3 (2004) 23-32
80. Dixit V.D., Schaffer E.M., Pyle R.S., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Commun Inq 114 1 (2004) 57-66